Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Multicenter, Randomized, Double-Blinded Safety Study

Administered By

Awarded By

Contributors

Start/End

  • February 1, 2018 - January 31, 2020